Navigation Links
MediVoice Announces Appointment of Edward J. Zecchini as Chief Operating Officer & Chief Technology Officer
Date:5/19/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 2Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 3Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 4Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 5Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 6Health News:New Health Report Exposes Imminent Risk of a Stroke Crisis in Europe 7Health News:Book Offers Help for Parents Struggling with Difficult Teens During the Upcoming Holidays 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 2Health News:Orlando Company Develops New Technology Designed To Help Combat Hospital-Acquired Infections 3Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 2Health News:Lumetra Healthcare Solutions Begins Contract With City and County of San Francisco 3Health News:2010 Will Be a Great Year for a Change! Start a New Career Now! 2
Breaking Medicine Technology:Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 2Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly 3Free Wheelchair Mission Breaks List of Top 60 OC Nonprofits in 2009 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Cephalon Quarterly Conference Call Invitation 12853 1Police work undermines cardiovascular health comparison to general population shows 50430 1Police work undermines cardiovascular health comparison to general population shows 50430 2Police work undermines cardiovascular health comparison to general population shows 50430 3Bladder Cancer No Longer a Death Sentence 50427 1Bladder Cancer No Longer a Death Sentence 50427 2Bladder Cancer No Longer a Death Sentence 50427 3